New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22825583.
- Also identified by DOI 10.1158/1078-0432.CCR-11-2375 and PMC identifier 3432735.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM, ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.
Medical subject headings
- Mesothelioma
- Neurofibromatosis 2
- Tumor Suppressor Proteins
- Ubiquitin Thiolesterase